In addition to cardiovascular benefits, dual GLP-1/amylin therapy is now being studied in various obesity-related conditions like nonalcoholic steatohepatitis, obstructive sleep apnea, chronic kidney disease, and heart failure with preserved ejection fraction, suggesting that these drugs could be used as a cornerstone therapy for the management of comprehensive metabolic syndrome rather than for just one indication
Ongoing Research and Future Developments Ongoing Research and Future Developments Ongoing research and future developments in the field of Semaglutide continue to explore new avenues for its application and potential improvements
Attenuated brain-derived neurotrophic factor and hypertrophic remodelling: The SABPA study
GLP-1R activation attenuates the progression of pulmonary fibrosis via disrupting NLRP3 inflammasome/PFKFB3-driven glycolysis interaction and histone lactylation
The Dangers of a Herniated Disc and How to Avoid Them March 9, 2023 How to Maintain Spinal Health During Pregnancy March 23, 2023 With chronic pain, everyday activities can become painful and difficult
Weight management in hypothyroid patients is a notable area where semaglutide shows promise